Does Frontline R2CHOP Reduce CNS Relapse Risk in DLBCL?

There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting.

Source: CancerNetwork - July 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news